Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Isoflavones composition and medicine made of same

A technology of isoflavones and methyl isoflavones, which is applied in the field of medicine and can solve the problems of large toxic and side effects

Inactive Publication Date: 2013-03-06
苏州同立医药技术有限公司
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these drugs have certain curative effect, they have serious side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Isoflavones composition and medicine made of same
  • Isoflavones composition and medicine made of same
  • Isoflavones composition and medicine made of same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Anti-leukemia Drug Efficacy Test in Mice

[0058] 1. Test method

[0059] The mouse lymphocytic leukemia cell line L1210 was subcultured in DMEM (GIBCO) medium containing 15% calf serum, and 20%-30% volume of fresh medium was added every 2-4 days. Culture conditions: 5% CO2, saturated humidity, 37°C.

[0060] The animals used were DBA / 2 inbred mice, 8-12 weeks old, half male and half male. Bought from Shanghai Slack Experimental Animal Co., Ltd. [SCXK (Shanghai) 2003-0003], take cultured cells in logarithmic growth phase, centrifuge at 1500r / min for 5min, discard supernatant, resuspend cells in serum-free DMEM, centrifuge at 1500r / min for 5min , Cell counting, each mouse was intraperitoneally injected with 0.1ml of cell suspension (containing 1×106 cells). DBA / 2 mice were randomly divided into 5 groups after inoculation: blank control group, positive drug doxorubicin (ADM) group (2mg / kg) and total flavonoids group (120mg / kg), two component groups ( 80mg / kg) and sing...

Embodiment 2

[0071] Drug Efficacy Test of Anti-transplanted Lung Cancer in Mice

[0072] 1. Test method

[0073] Mouse Lewis lung cancer cells cryopreserved in liquid nitrogen were resuscitated, and subcutaneously inoculated 5×105 / cell in the right axilla of 4 C57BL / 6 mice to prepare passage tumor-bearing mice. The mice were sacrificed after 3 passages, and the tumor mass of the tumor-bearing mice was stripped under aseptic conditions to prepare a 5×106 / mL tumor cell suspension, and then 0.2 mL of tumor cells were subcutaneously inoculated into the right axilla of mice in each group suspension. Stratified random grouping according to body weight, respectively blank control group, positive drug cisplatin (DDP) group (1mg / kg) and total flavonoids group (120mg / kg), two component groups (80mg / kg) and single component group ( 50mg / kg). 10 animals per group.

[0074] 7 days after inoculation, when the tumor grows to a volume of 100-200mm3, the drug is administered. The drug of the present inve...

Embodiment 3

[0085] Anti-transplanted Prostate Cancer Drug Efficacy Test

[0086] 1. Test method

[0087] Passaging in vivo: Human prostate cancer PC-3M cell line (purchased from Sino-US joint venture Bohuisi Biomedical Technology Co., Ltd.) cultured in vitro in logarithmic growth phase was digested with trypsin to prepare cell suspension, and the concentration was adjusted to 1× 107 / ml, inoculated subcutaneously in the right axilla of mice, 0.2mL / only. Three generations were passed continuously in vivo, and the tumor-bearing mice of the third generation were used as the tumor source for the experiment.

[0088] Inoculation: 2 weeks after inoculation, take well-grown human prostate cancer PC-3M tumor blocks in nude mice, add physiological saline, grind with a homogenizer to prepare a cell suspension, count and adjust the number of cells to 1×107 / ml, Each nude mouse was subcutaneously inoculated with 0.2ml in the right armpit, and stratified and randomly divided into groups according to b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an isoflavones composition and medicine made of the same. The isoflavones composition comprises methylophiopogonanone B, methylophiopogonanone A, 6-formylisoophiopogonone A, 5,7,2',6'-tetrahydroxy-4'-methoxyl-6,8-dimethylophiopogonanone, ophiopogonanone E, 5,7,4'-trihydroxy-3'-methoxyl-6,8-dimethylophiopogonanone, 2,5,7- trihydroxy-4'-methoxyl-6,8-dimethylophiopogonanone, 6-formylisoophiopogonone B, 5,7,4'-trihydroxy-6-dimethylophiopogonanone and 5,7,4'-trihydroxy-6-methylophiopogonanone. The medicine can be used for treatment and prevention of cancers.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to an isoflavone component and a medicine prepared therefrom. Background technique [0002] The mortality rate of malignant tumors is increasing year by year, and it is an important disease that affects human life and health. According to the WHO "World Health Statistics 2008" report, it is estimated that the mortality rate of non-communicable diseases will increase significantly in low- and middle-income countries in the world after 25 years; the global cancer mortality rate will rise from 74 / 100,000 in 2004 to 118 / 100,000 (2030), second only to cardiovascular disease, and the mortality rate ranks second among all causes of death. Classified by disease type, among all causes of death in 2004, lung cancer ranked 8th, gastric cancer ranked 17th, and colorectal cancer ranked 20th. It is estimated that by 2030, lung cancer will rise to 6th, and gastric cancer will rise to 9th , co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/36A61K31/352A61P35/00A61P35/02A61P11/00A61P13/08A61P15/14
Inventor 袁宁生夏玉叶闵旸
Owner 苏州同立医药技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com